Bavarian Nordic has revealed a new Phase II trial that will explore a combination of its cancer vaccine, CV301, and Bristol-Myers Squibb’s nivolumab (OPDIVO) for treating patients with metastatic colorectal cancer (mCRC).

Led by Rutgers Cancer Institute in New Jersey, US, Liver Cancer and Bile Duct Cancer Programme director Dr Darren Carpizo, the trial will enrol up to 74 patients with oligometastatic, microsatellite stable mCRC eligible for complete resection.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

As part of the trial patients will be randomised to receive four cycles of either chemotherapy plus nivolumab or a combination of chemotherapy, nivolumab, and CV301, before the surgical removal of their tumours.

Following resection, patients will continue to receive respective treatments in each study group.

The trial aims to begin enrolment soon.

“By exploring unique combinations of vaccine therapy and checkpoint inhibition along with standard of care, we believe it is possible to improve overall survival.”

Dr Carpizo said: “In about 80% of colorectal cancer patients whose disease has spread to the liver, the cancer returns after complete resection.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“By exploring unique combinations of vaccine therapy and checkpoint inhibition along with standard of care, we believe it is possible to improve overall survival and risk of recurrence in this patient population.”

Bavarian Nordic president and CEO Paul Chaplin noted that so far no checkpoint inhibitors have been approved for the treatment of microsatellite stable colorectal cancer.

Chaplin said: “We believe that CV301, with its ability to elicit T-cells against specific tumour antigens, has the potential to address cancers in which monotherapy checkpoint inhibition may not be possible, and we are happy to further explore how we can best serve patients in need of new therapies.”

CV301 is Bavarian’s immunotherapy candidate, which is being developed under a cooperative research and development agreement (CRADA) with the US National Cancer Institute (NCI).